Regeneron Inc.'s Zaltrap (ziv-aflibercept) won FDA approval Friday in metastatic colorectal cancer, for use in combination with FOLFIRI (folinic acid, fluorouracil and irinotecan) chemotherapy, a little more than a year after surprising investors with positive data in a pivotal trial.